European Survey on the Management of Glanzmann's Thrombasthenia
The EAHAD Glanzmann's Thrombasthenia Working Group (GTWG) has recently been formed and is pleased to announce their first project, the European Initiative on Glanzmann's Thrombasthenia* to further understand the diagnosis, treatment, unmet needs and overall management of this patient population. This Initiative is funded by an educational grant from Novo Nordisk and aims to raise awareness of this rare disorder, as well as related conditions, with the ultimate aim of improving patient care.
The GTWG invites you to contribute to this initiative by completing this survey, which will ask about your experience of GT management in your clinical practice. We would welcome responses from all physicians across Europe, who have managed or are currently managing patients with GT.
This survey consists of questions that are easy to respond to from memory, without consulting clinical practice records.
Your responses to this survey will help to generate a valuable snapshot of how this rare and debilitating bleeding disorder is currently diagnosed and managed in clinical practice, which is also planned for publication following statistical analysis.
Thank you very much for supporting this valuable initiative,
The EAHAD Glanzmann's Thrombasthenia Working Group,
including the project steering committee, Roseline d’Oiron, Mathieu Fiore, Andrea Artoni, Robert Klamroth, Mary Mathias, and Roger Schutgens.
*Glanzmann's Thrombasthenia (GT) is a rare autosomal recessive disorder, characterised by spontaneous and trauma-related mucocutaneous bleeding, with variable expression ranging from easy bruising to fatal haemorrhages. Despite several reports on management of patients with GT, there is currently no European consensus.